Ipamorelin 5 mg

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It does not occur in nature. The molecule originated in a Novo Nordisk peptide programme under the development code NNC 26-0161 and was characterised by Raun and colleagues in 1998. They identified it within a series lacking the central Ala-Trp dipeptide of growth-hormone-releasing peptide-1.

Four features define its chemistry. The N-terminal residue is Aib, an achiral non-standard amino acid. Positions three and four are D-amino acids: D-2-naphthylalanine and D-phenylalanine. The C-terminus is a carboxamide rather than a free acid. The standard residues are L-histidine and L-lysine. This structure differs from both the longer GHRH peptides and ghrelin, which carries a lipid modification. Ipamorelin has no cysteine and no disulfide bridge.

The free-peptide formula is C38H49N9O5 and its molecular mass is approximately 711.87 g/mol. Counter-ions and bound water can contribute additional mass in a dried preparation, so gross powder mass and net peptide mass are not automatically identical. These chemical distinctions do not establish the salt form, purity or net content of this 5 mg listing; those require the applicable analytical specification.

Raun and colleagues studied hormone release in rat pituitary cells, rats and pigs. Their comparisons with other secretagogues described receptor-related activity and hormone selectivity under those conditions, not a general human safety guarantee. Later rodent studies examined bone growth and mineral content. In the Svensson study, the increase in mineral content disappeared after adjustment for body-weight change, while volumetric bone mineral density was unchanged.

Gobburu and colleagues investigated pharmacokinetics and growth-hormone responses in healthy male volunteers. A different clinical programme concerned postoperative bowel function. In Beck and colleagues’ randomised proof-of-concept study, the median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant (p = 0.15). The authors found no significant difference in the key or secondary efficacy analyses. These particular study endpoints should not be converted into claims about muscle growth, recovery or this supplied vial.